Idexx Laboratories Inc (NASDAQ:IDXX) reported third-quarter adjusted EPS of $2.79, up 12% year-over-year, beating the consensus of $2.68.
The company reported sales of $975.54 million, an increase of 7% as reported and 6% organically, missing the consensus of consensus of $979.18 million.
Organic revenue growth is supported by benefits from IDEXX execution drivers, including continued solid new business gains and double-digit year-over-year global premium installed base growth.
The revenue growth was driven by Companion Animal growth of 7%, as reported, and 6% organic, and Water revenue growth of 13% as reported and organic.
“IDEXX teams continued their strong execution in the third quarter as demonstrated by solid net customer gains, continued growth in our premium IDEXX VetLab instrument installed base, and ...